Podcasts about Disease

Unexpected rates of sickness (morbidity) has sunk the stock price of a major US health insurer (Centene or CNC). Maybe now we can finally have an open conversation about the causes?Click Here for Part 2

In this episode, Melanie Perrier, DrMedVet, DACVS, DECVS, CERP, discussed some of the equine rehabilitation modalities she commonly uses in practice, including mesotherapy, laser therapy, and kinesiotape. She talked about how she decides which modalities to incorporate into her treatment plan when evaluating a case for rehabilitation, and she offered advice for veterinarians interested in expanding their rehabilitation offerings.This episode of Disease Du Jour is brought to you by Equithrive.Disease Du Jour Podcast Hosts, Guests, and Links Episode 161:Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)Guest: Dr. Melanie Perrier, DrMedVet, DACVS, DECVS, CERPPodcast Website: Disease Du JourThis episode of Disease Du Jour podcast is brought to you by Equithrive.Connect with the Host:Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)

Host: Darryl S. Chutka, M.D. Guest: Edward V. Loftus JR, M.D. Inflammatory Bowel Disease is somewhat of an umbrella term for a group of chronic inflammatory conditions of the GI tract. The most common types include ulcerative colitis and Crohn's Disease. While there are similarities between the two, there are also differences. For many individuals with inflammatory bowel disease, it's only a mild illness. Unfortunately for some, it can lead to severe disability and potentially life-threatening complications. What are the similarities and differences between ulcerative colitis and Crohn's? When should we suspect a patient has an inflammatory bowel disease? What's the best way to establish a diagnosis and finally, what treatment options do we have? These are just some of the questions I'll be asking my guest, Edward V. Loftus JR, M.D., from the Division of Gastroenterology and Hepatology at the Mayo Clinic as we discuss “Inflammatory Bowel Disease and Its Treatment”. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts 

In this episode, Dinesh discusses Elon Musk’s “red alert” over our escalating national debt, and explores the best way to solve it. Dinesh shows why Zohran Mamdani’s idea for government-owned grocery stores is based on a hoax and a misunderstanding. Author and actress Ann-Marie Murrell joins Dinesh to talk about the pains and ultimate satisfactions of caring for a parent with Alzheimer’s Disease.See omnystudio.com/listener for privacy information.

Thank you for tuning in for another episode of Life's Best Medicine. Dr. Carl Rothschild is the founder, researcher, and owner of Trifecta Light Technologies, Inc., the industry leader in the LED Infrared/Red Light therapeutic heating light lamp modality. He is widely considered one of the world's top thought leaders in LED Infrared/Red Light science and products. In this episode, Drs. Brian and Carl talk about… (00:00) Intro (04:46) How Dr. Carl first became aware of amazing benefits of red light therapy (08:10) Some of the ways light therapy can be used to heal the body (15:07) Why practically everyone benefits from red light therapy (20:03) The mechanisms by which red light works in the body to increase fat-loss (22:00) How near infrared light stimulates the mitochondria (29:06) The fat-loss benefits of red light therapy (37:57) How red light therapy works to repair skin (38:59) Red light therapy for athletes (43:53) Pharmaceutical drugs (45:10) Red light therapy for Parkinson's Disease (46:16) Red light therapy side effects and why it still remains a fringe treatment modality (49:51) Insulin resistance and red light therapy (51:42) Staying healthy and increasing your health span (55:22) Using other therapies in conjunction with red light (59:05) Outro For more information, please see the links below. Thank you for listening!   Links:   Dr. Carl Rothschild: IG: https://www.instagram.com/trifectalightofficial/ FB: https://www.facebook.com/trifectalightofficial YouTube: https://www.youtube.com/@trifectalightofficial Trifecta Light: https://trifectalight.com Illuminated Healing (book): https://trifectalight.com/books/   Dr. Brian Lenzkes:  Arizona Metabolic Health: https://arizonametabolichealth.com/ Low Carb MD Podcast: https://www.lowcarbmd.com/   HLTH Code: HLTH Code Promo Code: METHEALTH • • HLTH Code Website: https://gethlth.com

This week i detail the baseball journey of pitching great Warren Spahn. By the time, his long and prolific career was in the books, he had amassed the most victories (363) in the game's history for a left-handed pitcher, the sixth most wins of all time and the most wins ever by a pitcher who pitched exclusively in the live-ball, modern era. All of his brilliance is magnified by the fact that he doesn't record his first win until he is 25 years old. He misses three years of Major League baseball in service to the United States during World War II. During the war, he is a hero at the Battle of the Bulge in Bastogne, Belgium. His exploits defending the Ramagen Bridge in Germany, earns him a battlefield promotion, a Purple Heart, a Bronze Star, and a Presidential Citation, making him the most decorated Major League player during World War II. From humble beginnings in blue-collar Buffalo, New York during the Great Depression to the pantheon of of immortals in Cooperstown, we follow his long, amazing career. We also say our solemn goodbyes to "The Cobra" Dave Parker who succombed to his 10 year battle with Parkinson's Disease. #WarrenSpahn #MilwaukeeBraves #BostonBraves

Epilepsy is a neurological condition that causes seizures, but throughout history, it was thought to be caused by demonic possession, angry gods and evil spirits. In this episode we discuss what Epilepsy is, and its medical and social history.

Chadi sits down with Lou Weisbach, entrepreneur and founder of the American Center for Cures, who shares his ambitious mission to raise $750 billion through an innovative public-private bond model to accelerate the prevention and cure of chronic diseases like cancer, Alzheimer's, diabetes, and Parkinson's. Weisbach discusses how his model is designed to align incentives across government, industry, and research institutions, bridging political divides and pharmaceutical interests to focus on cure-based rather than treatment-based outcomes. He also reflects on two decades of groundwork, key milestones achieved, and how the initiative operates day-to-day, including the development of disease-specific platforms poised to transform biomedical research and public health. Find out more about his cause. https://theamericancenterforcures.org/ Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Commentary by Dr. Jian'an Wang.

Struggling with a bloated stomach after eating or chronic abdominal distension? In this episode, I'll explain why dysfunction in three major systems causes bloating and reveal 5 evidence-based microbiome fixes that can help reduce stomach bloating while healing your gut naturally.   Start healing with us! Learn more about our virtual clinic:  https://drruscio.com/virtual-clinic/   Free downloadable Low FODMAP Diet guide: https://drruscio.com/guides/get-low-fodmap-diet-guide/   Featured products: Elemental Diet: https://store.drruscio.com/products/elemental-heal Triple Therapy Probiotics: https://store.drruscio.com/products/triple-therapy-probiotic Biota Clear Series: https://store.drruscio.com/search?q=biota+clear Biota Dissolve: https://store.drruscio.com/products/biota-dissolve VaguStim: https://vagustim.io/  

About this episode: Since the 1950s, companies have been using PFAS—or “forever chemicals”—to manufacture everyday household items from waterproof mascara to shaving cream to Bandaids. Research and advocacy have not only linked these chemicals to certain cancers, liver disease, and fertility issues, but they have also posited that 97% of Americans have traces of PFAS in their blood. In this episode: guest host Tom Burke talks with writer Rachel Frazin about her new book outlining the dark history of PFAS in American manufacturing, the communities across the country demanding accountability and regulation, and the near future of regulation of drinking water. Guest: Rachel Frazin covers energy and environmental policy for The Hill and is the co-author of the book Poisoning the Well: How Forever Chemicals Contaminated America. Host: Dr. Tom Burke is an emeritus professor at Johns Hopkins and a former top official with the Environmental Protection Agency in the Obama administration. Show links and related content: Poisoning the Well: How Forever Chemicals Contaminated America (book)—Island Press Exposure to “forever chemicals” before birth may raise blood pressure during teen years–American Heart Association Trump Administration to Uphold Some PFAS Limits but Eliminate Others—The New York Times What You Need to Know About PFAS, Or “Forever Chemicals”—Public Health On Call (April 2024) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

The man, the myth, and the legend returns!  Glenn Longabaugh returns to the podcast room with hosts Jeff Jarrett and Sal Sama for this episode of The High Ground powered by Premier Companies.  Of course, Glenn is the Technical Agronomist for Premier Companies, but you may not know he's practically an expert on suck holes and vole colonies.  Glenn will share an update on the current growing season and how the weather conditions have impacted each farmer's ability to get their fields planted.  You'll also learn why Glenn isn't worried about the tar spot findings from pathologists and why small plants aren't great hosts.  Sal, Jeff, and Glenn dig into how diseases become epidemics in the reproductive stage and the various stages of the disease triangle and why it should be considered a disease square instead.  You'll also hear about Glenn's top watchouts given our recent rainfall events and the reasons behind the greensnap corn in Premier's territory.  “I don't want to condemn this crop…  I'm telling you, there's a lot of potential out there.”

What really happened at Jamestown, America's first permanent English settlement? Today we dive into one of the most brutal and fascinating stories in early American history—from hopeful beginnings to starvation, cannibalism, and chaos. Who were the people that risked everything to build a new world? What went so wrong? And how did Jamestown barely survive long enough to become the foundation of the future United States? This is a story of ambition, failure, survival, and secrets buried in the swamp… WELCOME TO CAMP

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AWM865. CME/MOC/AAPA credit will be available until June 30, 2026.Strategies for Immunotherapy Success in NSCLC: How to Incorporate Modern ICI Platforms Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., Rahway, NJ, USA, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

En este episodio exclusivo, LamboRaúl cuenta por primera vez en español su historia completa: cómo pasó de estar hospitalizado con Crohn's Disease y soñar con entrar al ejército, a convertirse en uno de los primeros traders latinos en recibir un payout de más de $100,000 en EE.UU.Raúl revela los inicios duros, su obsesión con educarse en trading, y cómo fue escalando en los mercados de divisas, commodities y futuros. También habla de psicología del trader, errores por ego, cómo construyó su firma de fondeo, y el precio real del éxito.Más allá del dinero y los superdeportivos, este episodio profundiza en la relación con su padre, su transformación espiritual, y lo que realmente le da sentido a su vida hoy: su fe, su familia y ayudar a otros a crecer.Una historia cruda, honesta y poderosa sobre disciplina, caídas, redención y visión. Imperdible.#DalePlay y #LearnWhileInvesting

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AWM865. CME/MOC/AAPA credit will be available until June 30, 2026.Strategies for Immunotherapy Success in NSCLC: How to Incorporate Modern ICI Platforms Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., Rahway, NJ, USA, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Hey guys, We're back again with another episode! This week Deja shares her professional opinion on private versus public school. We move on to discuss "professionalism" in white spaces and how we show up in our full Blackness in the workplace and academic settings. We then delve into the themes of the blockbuster movie 'Sinners' such as culture appropriation, African spirituality, resistance and liberatio

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AWM865. CME/MOC/AAPA credit will be available until June 30, 2026.Strategies for Immunotherapy Success in NSCLC: How to Incorporate Modern ICI Platforms Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., Rahway, NJ, USA, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

What should you eat to optimize brain health and cognitive performance? Are there key micronutrients that form the foundation for long-term health and longevity? In today's episode, Dr. John E. Lewis joins us to share his insight on exercise, nutrition, and his fascinating research on the power of polysaccharides… Hit play now to explore: What polysaccharides are, and how to harness them. The gold standard for assessing cognitive function. The benefits of consistent and intense workouts for overall health. Why Alzheimer's symptoms differ amongst various patients.  Dr. Lewis is the Founder and President of Dr. Lewis Nutrition and a former associate professor in the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine. With over 180 peer-reviewed publications in leading scientific journals, he has served as the principal investigator for more than 30 studies throughout his research career. His work primarily focuses on evaluating the impact of nutrition, dietary supplementation, and exercise on various aspects of human health.  Want to learn more about Dr. Lewis's extraordinary commitment to health and how he has worked to combat Alzheimer's Disease and a host of other neuro-degenerative conditions? Tune in now! Keep up with Dr. Lewis's socials here: Instagram: https://instagram.com/DrLewisNutrition/ Facebook: https://facebook.com/DrLewisNutrition/ TikTok: https://tiktok.com/@DrLewisNutrition/ YouTube: https://youtube.com/@DrLewisNutrition/ Episode also available on Apple Podcasts: http://apple.co/30PvU9C

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

Episode #115 is all about diving into the midlife woman's brain—your most vital, complex, and vulnerable organ—and why protecting it matters more than ever. Here's a fact that doesn't get enough attention: two out of three people with Alzheimer's are women. And this isn't just about old age. The seeds of cognitive decline can start as early as your 40s—or even sooner.We'll talk about:• Why women are at greater risk for Alzheimer's and dementia• The brain-hormone connection during menopause and midlife• What you can do now to preserve memory, focus, and cognitive resilience• How genes like APOE4 interact with lifestyle—and what that means• How belly fat, or visceral fat. Affect cognition and brain health• And the power of early, personalized preventionMy guest, Dr. Kellyann Niotis, MD, is the first fellowship-trained preventive neurologist in the world, specializing in risk reduction strategies for neurodegenerative disorders such as Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease. Dr. Niotis led the preventive neurology program within Dr. Peter Attia's medical practice, Early Medical, and managed the country's first Alzheimer's Prevention Clinic at Weill Cornell Medical College/NewYork-Presbyterian Hospital, where she developed research programs for Parkinson's and Lewy Body Dementia prevention. Her work has been published in several medical journals, including Neurology, Nature Mental Health, Frontiers of Aging Neuroscience, Aging and Disease, Movement Disorders, Journal of Alzheimer's Disease, Alzheimer's & Dementia, and Journal of the Prevention of Alzheimer's Diseas,e and has been presented at national and international conferences.She is passionate about the budding medical space of preventive neurology, in particular pertaining to the advocacy of preventive neurology policy changes and making treatment & education more accessible to the masses. She has received numerous honors and awards, and her opinions have been featured in popular media outlets, including CNN.Whether you're looking for tools to sharpen your brain today or you're thinking long-term about protecting yourself and your loved ones, this conversation is full of insight and hope.Medical Disclaimer:By listening to this podcast, you agree not to use this podcast as medical advice or to make any lifestyle changes to treat any medical condition in yourself or others. Consult your own physician for any medical issues that you may be having. This entire disclaimer also applies to any of my guests on my podcast.Learn more about Dr. Niotis:Website: https://drkellyannniotis.com/IG: @drkellyannniotisFB: @drkellyannniotisResources:Lancet Commission Modifiable Risk Factor list:https://www.thelancet.com/infographics-do/dementia-riskStay connected with JFW:Watch on my YouTube channel: https://www.youtube.com/@jillfooswellness/videosFollow me on Instagram: https://www.instagram.com/jillfooswellness/Follow me on Facebook: https://www.facebook.com/jillfooswellnessGrab discounts on my favorite biohacking products: https://www.jillfooswellness.com/health-productsEnjoy 20% savings and free shipping at Fullscript for your favorite supplements by leading brands:https://us.fullscript.com/welcome/jillfooswellnessSubscribe to the JFW newsletter at www.jillfooswellness.com and receive your FREE Guide on How To Increase Your Protein in 5 Easy Steps and your free Protein Powder Recipe Ebook. Schedule your complimentary 30-minute Zoom consultation here:https://calendly.com/jillfooswellness/30-minute-zoom-consultations

Enjoy these back to back throwback episodes! Doors of Perception is available now on Amazon Prime!https://watch.amazon.com/detail?gti=amzn1.dv.gti.8a60e6c7-678d-4502-b335-adfbb30697b8&ref_=atv_lp_share_mv&r=webMake a Donation to Forbidden Knowledge News https://www.paypal.me/forbiddenknowledgenehttps://buymeacoffee.com/forbiddenThe Forbidden Documentary: Doors of Perception official trailerhttps://youtu.be/F-VJ01kMSII?si=Ee6xwtUONA18HNLZMerchhttps://fknstore.net/Start your microdosing journey with BrainsupremeGet 15% off your order here!!https://brainsupreme.co/discount/FKN15Book a free consultation with Jennifer Halcame Emailjenniferhalcame@gmail.comFacebook pagehttps://www.facebook.com/profile.php?id=61561665957079&mibextid=ZbWKwLWatch The Forbidden Documentary: Occult Louisiana on Tubi: https://link.tubi.tv/pGXW6chxCJbC60 PurplePowerhttps://go.shopc60.com/FORBIDDEN10/or use coupon code knowledge10FKN Link Treehttps://linktr.ee/FKNlinksForbidden Knowledge Network https://forbiddenknowledge.news/ Johnny Larson's artworkhttps://www.patreon.com/JohnnyLarsonSign up on Rokfin!https://rokfin.com/fknplusPodcastshttps://www.spreaker.com/show/forbiddenAvailable on all platforms Support FKN on Spreaker https://spreaker.page.link/KoPgfbEq8kcsR5oj9FKN ON Rumblehttps://rumble.com/c/FKNpGet Cory Hughes Book!Audio bookhttps://buymeacoffee.com/jfkbook/e/392579https://www.buymeacoffee.com/jfkbookhttps://www.amazon.com/Warning-History-Cory-Hughes/dp/B0CL14VQY6/ref=mp_s_a_1_1?crid=72HEFZQA7TAP&keywords=a+warning+from+history+cory+hughes&qid=1698861279&sprefix=a+warning+fro%2Caps%2C121&sr=8-1https://coryhughes.org/YouTube https://youtube.com/@fknclipspBecome Self-Sufficient With A Food Forest!!https://foodforestabundance.com/get-started/?ref=CHRISTOPHERMATHUse coupon code: FORBIDDEN for discountsOur Facebook pageshttps://www.facebook.com/forbiddenknowledgenewsconspiracy/https://www.facebook.com/FKNNetwork/Instagram @forbiddenknowledgenews1@forbiddenknowledgenetworkXhttps://x.com/ForbiddenKnow10?t=uO5AqEtDuHdF9fXYtCUtfw&s=09Email meforbiddenknowledgenews@gmail.comsome music thanks to:https://www.bensound.com/Become a supporter of this podcast: https://www.spreaker.com/podcast/forbidden-knowledge-news--3589233/support.

Support the show

Mark Anderson of Anderson's Seed and Garden talks about diseases and insects in your garden. He also took caller's questions about how to treat and plant trees in your yard.

A big old copper beech tree is a focal point of my garden, and each time I look out the window at it admiringly these days, I feel the same love and gratitude I always have for its grandeur –... Read More ›

This weekend broke us. Laura got hit with a foam sword at LARPing in Prospect Park,  Mae barely survived the NYC heatwave with a baby in tow, and Coney Island? An actual hellscape of broken glass, trash fires, and emotional damage. We recap our chaotic social calendars (why did we say yes to everything?), debate whether mental illness is actually contagious through kissing, and break down Jeff Bezos' $10M wedding in Venice — private jets, Oprah, and protestors on inflatable crocodiles included.Plus: a dog lawsuit that made us cry, AI layoffs that made us mad, and a foam arrow to the butt that Laura will never emotionally recover from.You can watch the full episode on YouTube
Make sure to check out Laura's Don't Tell Comedy Special and leave a comment telling her she looks amazing.Follow us on Instagram @Laurasogar and @mae_planert and you can watch full video of the episodes on YouTube.Like, follow, and tell your emotionally unwell group chat.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NVF865. CME credit will be available until June 29, 2026.Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, The Desmoid Tumor Research Foundation and Sarcoma Alliance for Research through Collaboration. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

We’re checking in on how the weather is treating wine grapes. David Korb is the owner, vintner and grape grower at Drumlin Ridge Winery in Waunakee, just North of Madison. Dave is hoping for dry weather these next few months to keep the wine grapes healthy. He's heard of a few issues statewide with winter kill and wind damage.See omnystudio.com/listener for privacy information.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NVF865. CME credit will be available until June 29, 2026.Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, The Desmoid Tumor Research Foundation and Sarcoma Alliance for Research through Collaboration. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

Hey Heal Squad! We're continuing our theme this week of gut, brain, and emotional healing with this week's throwback with triple board certified physician, Dr. Zach Bush! We knew this was the perfect time to bring back one of our favorite episodes to revisit this week.  Dr. Zach doesn't just talk about symptoms, he gets to the real root of disease: disconnection. Disconnection from our bodies, our relationships, our food, our purpose, and even the Earth itself. He shares how trauma, toxins, gut health, and isolation all play a role in why we're sick, PLUS how healing starts when we finally begin to reconnect on every level. Get ready to shift your perspective on health completely. We talk about the power of nature, the soul-body connection, and why your body isn't broken (it's just been overwhelmed). If you're craving deeper healing and ready to get to the why behind what you're feeling… you don't want to miss this one!  -- HEAL SQUAD SOCIALS IG: https://www.instagram.com/healsquad/ TikTok: https://www.tiktok.com/@healsquadxmaria HEAL SQUAD RESOURCES: Heal Squad Website:https://www.healsquad.com/ Heal Squad x Patreon: https://www.patreon.com/HealSquad/membership Maria Menounos Website: https://www.mariamenounos.com My Curated Macy's Page: Shop My Macy's Storefront Prenuvo: Prenuvo.com/MARIA for $300 off Delete Me: https://bit.ly/43rkHwi   code: SQUAD EMR-Tek Red Light: https://emr-tek.com/discount/Maria30 for 30% off Airbnb: https://www.airbnb.com/  Join the In-Person Heal Retreat: https://www.canyonranch.com/stay/events/heal-retreat-with-maria-menounos/?location=lenox  GUEST RESOURCES: Instagram: https://www.instagram.com/zachbushmd/  Website: https://zachbushmd.com/  ABOUT MARIA MENOUNOS: Emmy Award-winning journalist, TV personality, actress, 2x NYT best-selling author, former pro-wrestler and brain tumor survivor, Maria Menounos' passion is to see others heal and to get better in all areas of life. ABOUT HEAL SQUAD x MARIA MENOUNOS: A daily digital talk-show that brings you the world's leading healers, experts, and celebrities to share groundbreaking secrets and tips to getting better in all areas of life. DISCLAIMER: This Podcast and all related content (published or distributed by or on behalf of Maria Menounos or http://Mariamenounos.com and http://healsquad.com) is for informational purposes only and may include information that is general in nature and that is not specific to you. Any information or opinions provided by guest experts or hosts featured within website or on Company's Podcast are their own; not those of Maria Menounos or the Company. Accordingly, Maria Menounos and the Company cannot be responsible for any results or consequences or actions you may take based on such information or opinions. This podcast is presented for exploratory purposes only. Published content is not intended to be used for preventing, diagnosing, or treating a specific illness. If you have, or suspect you may have, a health-care emergency, please contact a qualified health care professional for treatment.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:Disease concerns and frequently asked questions from a patient perspectiveManaging symptomsTreatment options and supportive careImportance of awareness and educationPresenters:Gideon Hirschfield, MA, MB BChir, FRCP, PhDLily and Terry Horner Chair in Autoimmune Liver Disease ResearchProfessor, Division of Gastroenterology and HepatologyUniversity of TorontoDirector, The Autoimmune and Rare Liver Disease ProgrammeDirector, Francis Family Liver ClinicToronto General Hospital, University Health NetworkOntario, CanadaJess N. Schnur, BSN-RNNational PBC Patient AdvocateAmerican Liver FoundationDonation Support Services CoordinatorLifeline of OhioColumbus, OhioTo learn more, see the programHear Me: Patient Perspectives on PBC

In this powerful episode of Heal Yourself with Sarah Dawkins, I sit down with Amy Stein, a chronic illness thriver and holistic guide, who shares her deeply personal 15-year healing journey. Amy opens up about the difference between healing and curing and why so many women with chronic pain and invisible illnesses are misdiagnosed or not diagnosed at all, by the conventional medical system.We talk about Amy's background as a medical researcher and how working with chronic pain patients ironically mirrored her own deteriorating health. She discusses being dismissed by doctors, the emotional toll of feeling unseen and unheard and how she finally reclaimed her health by tuning into her body's wisdom and embracing natural healing methods.You'll hear how Amy navigated multiple misdiagnoses, Lyme disease, mold exposure, food sensitivities and systemic inflammation, ultimately discovering that the body can either fight or heal but not both at the same time.If you've ever felt gaslit by the medical system or unsure where to turn next, this episode will empower you to trust yourself, listen to your body and explore holistic paths to healing.

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

In this episode, we sat down with Max Kane of Farm Match to discuss his healing journey from a debilitating chronic illness. Max shares how he healed his Crohn's Disease without any medication, just whole real (and raw) foods. We discuss how Max created Farm Match which connects food producers to consumers, the power of real foods, the stigma around raw meat and dairy, and more.Show references:1920's playgroundFind Farm MatchInstagram // @farmmatchWebsite // https://www.farmmatch.com/Youtube // https://www.youtube.com/@maxkane4302Find HomegrownInstagram // @Homegrown_education, @lizhaselmayer, @joeyhaselmayerWebsite // https://www.homegrowneducation.org/Natural home goods // Haselmayer GoodsFrom long-term disability to vibrant health—how Max Kane of Farm Match conquered chronic illness with real (raw) food

In this special episode of Health Matters, we explore the power of storytelling in a health journey. As part of the Art of Wellbeing series at Lincoln Center, a collaborative effort with NewYork-Presbyterian, the official Hospital for Lincoln Center for the Performing Arts, we attend a storytelling workshop with The Moth, a nonprofit dedicated to the art and craft of storytelling. The workshop guided attendees through telling a personal story about their own health, led by an expert instructor. Health Matters host Courtney Allison discusses the healing power of storytelling with workshop facilitator, Anna Roberts, and reflects on the importance of stories with Dr. Rita Charon, a general internist, founder of the field of narrative medicine, and chief of the Division of Narrative Medicine at Columbia. Dr. Charon helps train doctors to be better listeners so that they can treat the whole patient.Click here to learn more about the Art of Wellbeing and upcoming events.___Dr. Rita Charon is a general internist and literary scholar who originated the field of narrative medicine. She is Professor and Founding Chair of the Department of Medical Humanities and Ethics and Professor of Medicine at Columbia University. She completed her MD at Harvard in 1978 and PhD in English at Columbia in 1999, concentrating on narratology. Her research focuses on the consequences of narrative medicine practice, narrative medicine pedagogy, and health care team effectiveness.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Idaho Matters sits down with one doctor who is committed to patient care and educating the physicians of tomorrow.

Can cannabis really help manage Parkinson's symptoms? In this episode (watch on YouTube), we dive into the science, the possibilities, and the risks. From non-motor symptoms like sleep issues and anxiety to potential interactions with common Parkinson's medications, we break down what CBD and THC might offer. You'll also learn about the many forms of cannabis — including gummies, tinctures, topicals, patches, and more — and which options are most commonly used in Parkinson's care.  We'll also explore important drug interactions with levodopa, dopamine agonists, and antidepressants — plus how to talk to your doctor about trying cannabis safely. Whether you're a person with Parkinson's, a caregiver, or a clinician, this episode offers a balanced, evidence-based look at cannabis as part of a holistic PD care strategy. Access a free printable guide to Cannabis products here: https://pdeducation.thinkific.com/products/digital_downloads/cannabis4pd Help to support this channel and out efforts to educate the world about Parkinson's Disease and get access to personalized content: https://www.youtube.com/channel/UC0g3abv8hkaqZbGD8y1dfYQ/join  https://www.patreon.com/pdeducation  Please be sure to give support to our channel sponsors: Comfort Linen: https://comfortlinen.com/PARKINSONSDISEASEEDUCATION (15% off entire order when applying the code PARKINSONSDISEASEEDUCATION at checkout) Kizik Shoes: https://kizik.sjv.io/pdeducation Cure Hydration: https://lvnta.com/lv_XG06Rho8SSlXEq3qlV If you have products that you would like for me to review on the channel please send them here: Parkinson's Disease Education P.O. Box 1678 Broken Arrow, OK 74013 Medical Disclaimer: All information, content, and material of this video is for informational purposes only and not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Affiliate disclaimer: Keep in mind that links used for recommended products may earn me a commission when you make purchases. However, this does not impact what products I recommend. If I recommend a specific product it is because it has been vetted by myself or based on personal use. #parkinson #parkinsonsawareness #parkinsonsdisease #parkinsonsawareness #cannabiseducation #parkinsonssymptoms #movementdisorder #cannabidiol

In this episode Ed interviews a podcast alumni, Dr. Vinson Doyle of Louisiana State University. They discuss the evolution of cercospora taxonomy and how it may relate to soybean diseases. Additional Resources https://bsppjournals.onlinelibrary.wiley.com/doi/full/10.1111/ppa.13261 https://link.springer.com/article/10.1007/s10658-020-01969-z https://apsjournals.apsnet.org/doi/epdf/10.1094/PHYTO-12-15-0332-R https://apsjournals.apsnet.org/doi/epdf/10.1094/PDIS-02-25-0407-RE   How to cite the podcast: Zaworski, E. (Host) and Doyle, V. (Interviewee). S4:E24 (Podcast). Taxonomic Tumult: Cerospora Species and Soybean Diseases Part 1. 6/25/25. In I See Dead Plants. Crop Protection Network.   Transcript

Steve and Virginia sit down with Andrea Hughes, a dedicated caregiver whose mother was diagnosed with early-onset Alzheimer's Disease. Featured in the PBS documentary Matter of Mind: My Alzheimer's, Andrea shares her personal journey navigating the challenges of caregiving at a young age, balancing work and family responsibilities, and finding strength through community and storytelling. To learn more, visit the PBS documentary page, follow Andrea on Instagram @itsandreakrystal, and explore her work at candidcaregiverscollective.com.

We're celebrating God's faithfulness in letting us release 100 episodes of Compelled! Show notes (including all the mentioned episodes) @ https://compelledpodcast.com/episodes/celebrating-100-episodes Zach Fowler's favorite episodes:  #05 A Spiritual Suicide - Phillip Telfer: https://compelledpodcast.com/episodes/phillip-telfer #17 Doubts. Depression. Disease. - Ryan Dobson: https://compelledpodcast.com/episodes/ryan-dobson Becky Hetrick's favorite episode: #27 9/11 Survivor at the Pentagon - Brian Birdwell: https://compelledpodcast.com/episodes/brian-birdwell Atley Nugent's favorite episodes: #90 Healing After Rape - Teri Hrabovsky: https://compelledpodcast.com/episodes/teri-hrabovsky #86 Skipping Retirement. Living on Mission. - Brian Lynn: https://compelledpodcast.com/episodes/brian-lynn Will Jackson's favorite episodes: #65 Among the Cannibals & Headhunters - Steve Richardson: https://compelledpodcast.com/episodes/steve-richardson #87 KKK Terrorist Finds Christ - Tom Tarrants: https://compelledpodcast.com/episodes/tom-tarrants Tim Hull's favorite episodes: Tom Tarrants (see link above) #30 Forgiving My Kidnappers - Gracia Burnham: https://compelledpodcast.com/episodes/gracia-burnham Micah Foster's favorite episodes: #60 A Broken Man's Miraculous Fight for the Unborn - John Barros: https://compelledpodcast.com/episodes/john-barros #16 Falsely Accused & Sentenced to Life in Prison - Hannah Overton: https://compelledpodcast.com/episodes/hannah-overton Mark Weeber's favorite episode: #28 The Blessing of Disability - Jonathan Pacheco, Part 1: https://compelledpodcast.com/episodes/jonathan-pacheco-pt-1 Episodes that Paul mentioned #​42 Grief in Afghanistan: Testimony from a U.S. Navy Special Ops Teammate - Jim Payne: https://compelledpodcast.com/episodes/jim-payne #92 The Witness - Steven Matamoros: https://compelledpodcast.com/episodes/steven-matamoros Want to help us make the next 100 episodes of Compelled? Either make a one-time gift, or become a Monthly Partner at: https://compelledpodcast.com/donate ++++++++++++ Compelled is a seasonal podcast using gripping, immersive storytelling to celebrate the powerful ways God is transforming Christians around the world. These Christian testimonies are raw, true, and powerful. Be encouraged and let your faith be strengthened! Want to help make new episodes? Either make a one-time gift, or become a Monthly Partner at: https://compelledpodcast.com/donate Perks of being a Monthly Partner include: EARLY ACCESS to each new Compelled episode 1 week early! FULL LIBRARY of our unedited, behind-the-scenes interviews with each guest... over 100+ hours of additional stories and takeaways! Become a Monthly Partner by selecting the "Monthly" option during check-out.  Show notes, emails, and more at: https://compelledpodcast.com Compelled is a member of the Proclaim Podcast Network: https://proclaim.fm Learn more about your ad choices. Visit megaphone.fm/adchoices

TED Fellow and equity bioengineer Erika Moore investigates how cells controlling inflammation behave differently depending on a patient's background. By focusing on the "who" behind the disease, Moore is uncovering why certain diseases disproportionately affect certain ethnicities, paving the way for more inclusive and effective health care.Want to help shape TED's shows going forward? Fill out our survey!Become a TED Member today at https://ted.com/join Hosted on Acast. See acast.com/privacy for more information.

It's clear that artificial intelligence is going to be one of the most powerful forces shaping the future of humanity and the planet today and over the next two decades. Much of the AI discourse is negative or dystopian themed. Far too little AI news is highlighting how the planet's problems and the challenges humans face can be solved. In this conversation, futurist Jack Uldrich paints a picture of how we can collectively benefit from the advancements in artificial intelligence. Given the moving target of forecasting the future, Jack provides AI scenarios that he is 99% certain will occur, 75% certain, and 50% certain. He even provides a few scenarios that have a 25% and even 1% chances of happening. Jack says that we will see great leaps in diagnosing cancer and Alzheimer's Disease sooner. He is optimistic that AI can be used to address the effects of climate change and greatly assist in the pursuit of nuclear fusion. In what is becoming known as the “compressed century” - where there will be a century's worth of change in just a decade, Jack points out that “AI is doubling in capacity and capability every seven months” which means that the capabilities of AI in six years could be a thousand times more powerful than they are today. Jack doesn't see AI as a panacea. He points out that there will be job losses because of AI. He says that trust could be further eroded as a result of AI-generated deep fakes and fake news. He also points out that the “internet is broken” as we move from “social media to social production.” The conversation ends with Jack sharing his ideas around how purpose, faith, and trust will grow in importance to cope with the disruption AI is certain to bring. Jack Uldrich is a well-recognized global futurist, speaker, and the author of thirteen books, including a number of award-winning best sellers. He is a frequent speaker on technology, change management and leadership and has addressed hundreds of corporations, associations and not-for-profit organizations on five continents. He regularly makes television appearances on PBS's Frontline, the Science Channel, and the Discovery Channel, and is a frequent guest on major media outlets, including CNN, CNBC, Fox and National Public Radio.

Support the Institute today. https://www.nova.edu/give/index.html?area=Institute%20for%20Neuro-Immune%20Medicine&designation=INIM%20Grateful%20Patient%20Fund In this episode, Haylie Pomroy shares a conversation with Dane Johnson, a board-certified Functional Nutritionist, focusing on inflammatory bowel disease (IBD), including Crohn's disease. Dane discusses the power of community in the healing process, why IBD prevalence is increasing, and how man-made chemicals disrupt the microbiome. He emphasizes the importance of gut healing and explores biomarkers and symptom profiles specific to Crohn's disease. He also covers the critical connection between the nervous system and IBD, and introduces the S.H.I.E.L.D. program, designed to help individuals find personalized answers to chronic illness. Drawing from his own journey from illness in childhood to healing, Dane helps others reclaim their health and move beyond limiting beliefs. Tune in to the Hope and Help for Fatigue and Chronic Illness Podcast: Healing IBD Naturally: The Mind-Gut Approach. Get the Wheat Zoomer Test here. https://vibrant-wellness.com/tests/food-reaction/wheat-zoomer Sign up for the COVID-UPP Study: https://redcap.nova.edu/redcap/surveys/?s=RMEDJ7LKCX&_gl=1*1h830h7*_gcl_au*MTM2NDA0MTQyOS4xNzE1MDA0ODAy If you are interested in joining a Gulf War Illness (GWI) trial, please complete the Recruitment Registry Form. https://redcap.nova.edu/redcap/surveys/?s=Y9YF8JJWJRK8HEKL%20&_gl=1*1fipp18*_gcl_aw*R0NMLjE3MDc5MTgwMzIuRUFJYUlRb2JDaE1JeWNyUXVfcXFoQU1WU1pCYUJSM3AyQWRBRUFBWUFTQUFFZ0s1NWZEX0J3RQ..*_gcl_au*MTg2NjgwMDQ4Ni4xNzA3MTQwNzgx Learn more about INIM's Research Studies: https://www.nova.edu/nim/research-studies/index.html  Dane Johnson is a board-certified Functional Nutritionist and a Natural Medicine Practitioner specializing in Crohn's Disease and Ulcerative Colitis. He is the founder of CrohnsColitisLifestyle. He combines self-empowering resolve with holistic unity, the drive of an entrepreneur with the idealism of a Millennial inspired to make an impact. He has helped thousands of people eliminate their symptoms naturally and handled all public speaking, video content, market strategy, and managed a team of 10+ employees with the mission to create the most impactful Crohn's/Colitis program in the world. Instagram: https://www.instagram.com/danejohnson1/?hl=en  LinkedIn: https://www.linkedin.com/in/danejohnson1/  Learn more about the CrohnsColitisLifestyle:   Website: https://crohnscolitislifestyle.com/  Instagram: https://www.instagram.com/crohnscolitis_lifestyle/?hl=en  LinkedIn: https://www.linkedin.com/company/crohnscolitislifestyle.com/  YouTube: https://www.youtube.com/channel/UCf3Yhapgc2Qb16_MP7f-DuQ  Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet. Learn more about Haylie Pomroy's approach to wellness through her website: https://hayliepomroy.com Instagram: https://www.instagram.com/hayliepomroy  Facebook: https://www.facebook.com/hayliepomroy  YouTube: https://www.youtube.com/@hayliepomroy/videos  LinkedIn: https://www.linkedin.com/in/hayliepomroy/  X: https://x.com/hayliepomroy   Enjoy our show? Please leave us a 5-star review. You can also find this show on our YouTube channel. https://www.youtube.com/playlist?list=PL3C8vOR8mcZIEVxA9DFoG1Wy9WOPANlnD Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d Learn more about the Institute for Neuro-Immune Medicine here. Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM

Episode 39 - Actor and personal trainer Ollie McFarlane talks career, funny stories and overcoming 5 surgeries for short segment Hirschsprung's Disease to follow his dream of acting. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

On this New Movie Monday we return back to an England overrun by the Rage Virus Plague. We discuss the newest addition to the franchise and mythology since 28 Days Later, the new evolution and super powers of the Rage Virus Zombies, and the many versions of family in the Apocalypse. This is a huge movie that shoves in a lot of ideas and even some insane camp. Make sure you see this one on the biggest screen possible! Synopsis: A group of survivors of the rage virus live on a small island. When one of the group leaves the island on a mission into the mainland, he discovers secrets, wonders, and horrors that have mutated not only the infected but other survivors.  Starring: Jodie Comer, Aaron Taylor-Johnson, Ralph Fiennes, Alfie Williams, Jack O'Connell Written by Alex Garland Directed by Danny Boyle  Help us make our first feature length Messed Up Movie: https://www.misfitparade.com/mrcreamjeans Support the show on the Patreon: https://www.patreon.com/c/messedupmoviespod Watch our newest short film Sugar Tits Now! https://www.youtube.com/watch?v=Sz7leFqqo4g  

06 23 25 Corn Leaf Diseases and Fungicides by Ag PhD

Welcome to my first solo AMA episode in quite some time!  I recently submitted the second round of edits for my book. That excited me and inspired me to reach out on social media and invite questions from my listeners and community. In my conversation today, I dive into weight loss resistance and reverse dieting, and I also share what I have been doing over the past year to build muscle.  Join me for a transparent and candid conversation, interwoven with questions from listeners and social media followers, where I answer many of the questions that matter most to you. IN THIS EPISODE, YOU WILL LEARN: Why the death of my father inspired me to back away from fasting and focus on strength training Changing my mindset to prioritize strength over thinness How the sex hormone shifts during perimenopause and menopause affect body composition The benefits of reverse dieting to improve metabolic health          Using strength training to counteract the effects of sarcopenia Chronic stress and its impact on cortisol levels and metabolic health inflammation levels and toxins from personal care products, food, and the environment Importance of prioritizing sleep  Connecting with hormone-savvy healthcare providers The best supplements for overall health Connect with Cynthia Thurlow   Follow on Twitter Instagram LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Books mentioned: Estrogen Matters: Why Taking Hormones in Menopause Can Improve Women's Well-Being and Lengthen Their Lives—Without Raising the Risk of Breast Cancer by Dr. Avrum Bluming and Dr. Carol Tavris The XX Brain: The Groundbreaking Science Empowering Women to Maximize Cognitive Health and Prevent Alzheimer's Disease by Lisa Mosconi

Ultraprocessed foods are everywhere — and a lot of them are making us sick! These industrially processed foods are being linked to 32 different diseases, including type 2 diabetes, obesity, heart disease, cancer, and depression.    But UFPs make up more than HALF the foods we eat. More when it comes to the diets of children and young people. And it's no wonder — even foods marketed as "healthy" choices fall into this category.    So how do you know what's safe, and what's making you sick? Are all of them unhealthy?   Dr. Neal Barnard is here to guide us. He joins Chuck to explain how this one category of food is quietly fueling a public health crisis — and how you can protect yourself.   You'll learn: What qualifies as an ultraprocessed food — and why it matters– The difference between a healthy and unhealthy processed food– How these foods are designed to be addictive and override your hunger cues– What the latest research says about chronic disease risk– Simple, affordable swaps to cut ultraprocessed foods from your diet   Whether you're trying to lose weight, prevent disease, or eat more mindfully, this episode gives you the tools to take control of your health — starting with what's on your plate.   This episode is sponsored by The Gregory J. Reiter Memorial Fund, which supports organizations like the Physicians Committee that carry on Greg's passion and love for animals through rescue efforts, veganism, and wildlife conservation.   — — SHOW LINKS — — JAMA Processed Food Study https://bit.ly/UPFsHealthStudy — — — Gregory J. Reiter Memorial Fund https://gregoryreiterfund.org — — EVENTS — — NHA Conference Where: Cleveland, OH When: June 26-29, 2025 Tix & Speakers: https://bit.ly/NHAtix2025 20% off virtual tickets with code: PCRM20 $100 off in-person tickets with code: PCRM100 — — — International Conference on Nutrition in Medicine Where: Washington, DC When: August 14-16, 2025 Tix & Speakers: https://www.pcrm.org/icnm $50 off tickets with code: NUTRITION50 — — BECOME AN EXAM ROOM VIP — — Sign up: https://www.pcrm.org/examroomvip — — THIS IS US — — The Exam Room Podcast Instagram: https://www.instagram.com/theexamroompodcast — — — Chuck Carroll Instagram: https://www.instagram.com/ChuckCarrollWLC Facebook: https://www.facebook.com/ChuckCarrollWLC X: https://www.twitter.com/ChuckCarrollWLC — — — Physicians Committee Instagram: https://www.instagram.com/physicianscommittee Facebook: https://www.facebook.com/PCRM.org X: https://www.twitter.com/pcrm YouTube: https://www.youtube.com/user/PCRM Jobs: https://www.pcrm.org/careers — — SUBSCRIBE & SHARE — — 5-Star Success: Share Your Story Apple: https://apple.co/2JXBkpy​​ Spotify: https://spoti.fi/2pMLoY3 Please subscribe and give the show a 5-star rating on Apple Podcasts, Spotify, or many other podcast providers. Don't forget to share it with a friend for inspiration!

Scott Porter (Ginny & Georgia, Friday Night Lights) joins me this week to discuss his transition from singing wide receiver to acting and how his pursuit in Hollywood allowed him to reconnect with lost family. Scott talks about the unexpected challenges and growth he's experienced on Ginny & Georgia, including the surprises of the ‘balance' show's success on Netflix. We also get into overcoming anxiety before performances, his passion for spreading awareness for Huntington's Disease, and learning the most when a situation goes wrong. Thank you to our sponsors: